J 2022

Continuum of sensory profiles in diabetes mellitus patients with and without neuropathy and pain

RAPUTOVÁ, Jana, Aneta RAJDOVÁ, Jan VOLLERT, Iva ŠROTOVÁ, Cora REBHORN et. al.

Basic information

Original name

Continuum of sensory profiles in diabetes mellitus patients with and without neuropathy and pain

Authors

RAPUTOVÁ, Jana (203 Czech Republic, belonging to the institution), Aneta RAJDOVÁ (203 Czech Republic, belonging to the institution), Jan VOLLERT, Iva ŠROTOVÁ (203 Czech Republic, belonging to the institution), Cora REBHORN, Nurcan UECEYLER, Frank BIRKLEIN, Claudia SOMMER, Eva VLČKOVÁ (203 Czech Republic, belonging to the institution) and Josef BEDNAŘÍK (203 Czech Republic, guarantor, belonging to the institution)

Edition

European Journal of Pain, Amsterdam, Elsevier, 2022, 1090-3801

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30210 Clinical neurology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.600

RIV identification code

RIV/00216224:14110/22:00127722

Organization unit

Faculty of Medicine

UT WoS

000854563100001

Keywords in English

diabetes mellitus patients; sensory profiles; neuropathy; pain

Tags

International impact, Reviewed
Změněno: 5/1/2023 13:42, Mgr. Tereza Miškechová

Abstract

V originále

Background Quantitative sensory testing (QST) assesses the functional integrity of small and large nerve fibre afferents and central somatosensory pathways; QST was assumed to provide insight into the mechanisms of neuropathy. We analysed QST profiles and phenotypes in patients with diabetes mellitus to study whether these could differentiate patients with and without pain and neuropathy. Methods A standardized QST protocol was performed and 'loss and gain of function' abnormalities were analysed in four groups of subjects: diabetic patients with painful (pDSPN; n = 220) and non-painful distal symmetric polyneuropathy (nDSPN; n = 219), diabetic patients without neuropathy (DM; n = 23) and healthy non-diabetic subjects (n = 37). Based on the QST findings, diabetic subjects were further stratified into four predefined prototypic phenotypes: sensory loss (SL), thermal hyperalgesia (TH), mechanical hyperalgesia (MH) and healthy individuals. Results Patients in the pDSPN group showed the greatest hyposensitivity ('loss of function'), and DM patients showed the lowest, with statistically significant increases in thermal, thermal pain, mechanical and mechanical pain sensory thresholds. Accordingly, the frequency of the SL phenotype was significantly higher in the pDSPN subgroup (41.8%), than expected (p < 0.0042). The proportion of 'gain of function' abnormalities was low in both pDSPN and nDSPN patients without significant differences. Conclusions There is a continuum in the sensory profiles of diabetic patients, with a more pronounced sensory loss in pDSPN group probably reflecting somatosensory nerve fibre degeneration. An analysis of 'gain of function' abnormalities (allodynia, hyperalgesia) did not offer a key to understanding the pathophysiology of spontaneous diabetic peripheral neuropathic pain. Significance This article, using quantitative sensory testing profiles in large cohorts of diabetic patients with and without polyneuropathy and pain, presents a continuum in the sensory profiles of diabetic patients, with more pronounced 'loss of function' abnormalities in painful polyneuropathy patients. Painful diabetic polyneuropathy probably represents a 'more progressed' type of neuropathy with more pronounced somatosensory nerve fibre degeneration. The proportion of 'gain of function' sensory abnormalities was low, and these offer limited understanding of pathophysiological mechanisms of spontaneous neuropathic pain.

Links

ED1.1.00/02.0068, research and development project
Name: CEITEC - central european institute of technology
MUNI/A/1144/2021, interní kód MU
Name: Diagnostika a patofyziologie neuropatické bolesti a dalších symptomů a komorbidit neurologických onemocnění
Investor: Masaryk University